Continued Product Sales Growth
2024 product sales reached $133 million, a 2% increase from 2023, marking the second consecutive year of growth.
Significant Fourth Quarter Revenue
$80 million generated in the fourth quarter, driven by diverse revenue sources including the U.S. strategic national stockpile and international markets.
International Expansion Achievements
TPOXX received regulatory approval in Japan, and a notable $11 million sale in East Asia, more than doubling the largest prior sale in the region.
Strong Financial Position
SIGA ended the year with a cash balance of $155 million and no debt, reflecting strong financial discipline.
Strategic Partnerships for Long-term Growth
An exclusive license agreement with Vanderbilt University for monoclonal antibodies with potential to complement the TPOXX franchise.